| Literature DB >> 25971313 |
Stephanie C Talker1, Hanna C Koinig2,3, Maria Stadler4, Robert Graage5,6, Eva Klingler7, Andrea Ladinig8, Kerstin H Mair9, Sabine E Hammer10, Herbert Weissenböck11, Ralf Dürrwald12, Mathias Ritzmann13,14, Armin Saalmüller15, Wilhelm Gerner16.
Abstract
Although swine are natural hosts for influenza A viruses, the porcine T-cell response to swine influenza A virus (FLUAVsw) infection has been poorly characterized so far. We have studied Ki-67 expression and FLUAVsw-specific production of IFN-γ, TNF-α and IL-2 in CD4(+) and CD8β(+) T cells isolated from piglets that had been intratracheally infected with a H1N2 FLUAVsw isolate. IFN-γ(+)TNF-α(+)IL-2(+) multifunctional CD4(+) T cells were present in the blood of all infected animals at one or two weeks after primary infection and their frequency increased in four out of six animals after homologous secondary infection. These cells produced higher amounts of IFN-γ, TNF-α and IL-2 than did CD4(+) T cells that only produced a single cytokine. The vast majority of cytokine-producing CD4(+) T cells expressed CD8α, a marker associated with activation and memory formation in porcine CD4(+) T cells. Analysis of CD27 expression suggested that FLUAVsw-specific CD4(+) T cells included both central memory and effector memory populations. Three out of six animals showed a strong increase of Ki-67(+)perforin(+) CD8β(+) T cells in blood one week post infection. Blood-derived FLUAVsw-specific CD8β(+) T cells could be identified after an in vitro expansion phase and were multifunctional in terms of CD107a expression and co-production of IFN-γ and TNF-α. These data show that multifunctional T cells are generated in response to FLUAVsw infection of pigs, supporting the idea that T cells contribute to the efficient control of infection.Entities:
Mesh:
Year: 2015 PMID: 25971313 PMCID: PMC4429459 DOI: 10.1186/s13567-015-0182-3
Source DB: PubMed Journal: Vet Res ISSN: 0928-4249 Impact factor: 3.683
Antibody panels
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| |||||
| CD3 | PPT3 | IgG1 | PE | secondary antibodya | in house |
| CD4 | 74-12-4 | IgG2b | Alexa488 | secondary antibodyb | in house |
| CD8α | 11/295/33 | IgG2a | PE-Cy7 | secondary antibodyc | in house |
| CD27 | b30c7 | IgG1 | Alexa647 | directly conjugatedd | in house |
| CD45RC | 3a56 | IgG1 | PerCP-Cy5.5 | directly conjugatede | in house |
| SLA-DR | MSA3 | IgG2a | Qdot605 | directly conjugated | in housef |
| Ki-67 | B56 | IgG1 | V450 | directly conjugated | BD Biosciences |
|
| |||||
| CD3 | PPT3 | IgG1 | PE | secondary antibodya | in house |
| CD8β | PG164A | IgG2a | Alexa488 | Zenon labeling kitg | VMRD |
| CD27 | b30c7 | IgG1 | Alexa647 | directly conjugatedd | in house |
| SLA-DR | MSA3 | IgG2a | Qdot605 | directly conjugated | in housef |
| Perforin | δ-G9 | IgG2b | PerCP-eFluor710 | directly conjugated | eBioscience |
| Ki-67 | B56 | IgG1 | V450 | directly conjugated | BD Biosciences |
|
| |||||
| CD4 | 74-12-4 | IgG2b | Alexa488 | secondary antibodyb | in house |
| CD8α | 11/295/33 | IgG2a | PE-Cy7 | secondary antibodyc | in house |
| CD27 | b30c7 | IgG1 | BV421 | biotin-streptavidinh | in house |
| IFN-γ | P2G10 | IgG1 | PE | directly conjugated | BD Biosciences |
| TNF-α | MAb11 | IgG1 | BV605 | directly conjugated | BioLegend |
| IL-2 | A150D3F1 | IgG2a | APC | directly conjugatedi | Life Technologies |
|
| |||||
| CD3 | BB23-8E6-8C8 | IgG2a | PE-Cy7 | directly conjugated | BD Biosciences |
| CD8β | PG164A | IgG2a | Alexa488 | Zenon labeling kitg | VMRD |
| CD27 | b30c7 | IgG1 | BV421 | biotin-streptavidinh | in house |
| IFN-γ | P2G10 | IgG1 | PE | directly conjugated | BD Biosciences |
| TNF-α | MAb11 | IgG1 | BV605 | directly conjugated | BioLegend |
| IL-2 | A150D3F1 | IgG2a | APC | directly conjugatedi | Life Technologies |
|
| |||||
| CD4 | 74-12-4 | IgG2b | PerCP-Cy5.5 | directly conjugated | BD Biosciences |
| CD8β | PG164A | IgG2a | Alexa488 | secondary antibodyj | VMRD |
| CD107a | 4E9/11 | IgG1 | Alexa647 | directly conjugated | AbD Serotec |
| Pan-γδ | PPT16 | IgG2b | PE-Cy7 | biotin-streptavidink | in house |
| IFN-γ | P2G10 | IgG1 | PE | directly conjugated | BD Biosciences |
| TNF-α | MAb11 | IgG1 | BV605 | directly conjugated | BioLegend |
aGoat anti-Mouse IgG1-PE, Southern Biotech.
bGoat anti-Mouse IgG2b-Alexa488, Life Technologies.
cGoat anti-Mouse IgG2a-PE-Cy7, Southern Biotech.
dAlexa Fluor-647 Protein Labeling Kit, Life Technologies.
eLightning-Link™ PerCP-Cy5.5 Tandem Conjugation Kit, Innova Biosciences.
fCustom conjugation by Life Technologies.
gIgG2a-Alexa488 Zenon labeling kit, Life Technologies.
hStreptavidin-BV421, BioLegend.
iLightning-Link™ APC Conjugation Kit, Innova Biosciences.
jGoat anti-Mouse IgG2a-Alexa488, Life Technologies.
kStreptavidin-PE-Cy7, eBioscience.
Figure 1Clinical score and H1N2-neutralizing antibody titers. (A) From one week prior to the first infection until the end of the study either six or nine weeks post primary infection, piglets were daily monitored for clinical signs of disease. Auscultation score (solid line; 0 = physiologic, 1 = low-grade intensified vesicular, 2 = middle-grade intensified vesicular, 3 = high-grade intensified vesicular, 4 = bronchial, 5 = wheezing, 6 = rales, 7 = friction rub) and dyspnea score (dashed line; 0 = no dyspnea, 1 = dyspnea on exertion, 2 = dyspnea at rest, 3 = severe dyspnea) are shown for the three PBS-treated control animals (#1 to #3) and the six FLUAVsw-infected animals (#4 to #9). (B) Weekly collected serum samples were tested for H1N2-neutralizing antibodies by serum neutralization tests. Titers are expressed as the reciprocal neutralizing dose 50 (ND50). Data of PBS-treated (#1 to #3) and FLUAVsw-infected (#4 to #9) animals is shown in the time course following infections. (A and B) The background color in each diagram indicates different time spans: pre-infection (white), post primary infection (light grey) and post secondary infection (dark grey).
Figure 2Kinetics of Ki-67 CD8β and Ki-67 CD4 T cells in peripheral blood of FLUAVsw-infected pigs. Freshly isolated PBMCs were stained and analyzed for CD4, CD8α, CD8β, CD27, Ki-67 and perforin expression by FCM. (A) CD3+CD8β+ T cells were gated for Ki-67 expression and Ki-67+ cells were further analyzed for expression of CD27 and perforin. Perforin+ (red gate) and perforin− (grey gate) Ki-67+CD3+CD8β+ T cells were further subgated for quantitative analysis over the time course following infection. (C) CD3+CD4+ T cells were gated for Ki-67 expression and Ki-67+ cells were further analyzed for CD8α and CD27 expression. CD8α+ (red gate) and CD8α− (grey gate) Ki-67+CD3+CD4+ T cells were subgated for quantitative analysis over the time course following infection. (A and C) Exemplary raw data of animals #6 and #8, prior to infection and one week post infection, is shown. (B and D) Absolute numbers of Ki-67-expressing subsets within CD8β+ T cells (B) and CD4+ T cells (D) of six infected animals in the time course following infection. For calculation of absolute numbers, total lymphocyte counts were multiplied by percent values obtained by gating on the respective T-cell subpopulation.
Figure 3Kinetics of FLUAVsw-specific IFN-γ-producing T cells identified by ELISpot and H1N2-neutralizing antibody titers. For IFN-γ ELISpot, freshly isolated PBMCs were in vitro restimulated for 24 h with FLUAVsw (infection strain; MOI = 0.1). Mock- and medium-incubated cultures served as negative controls. Frequency of IFN-γ-producing cells within 3 × 105 PBMCs is displayed for FLUAVsw- (red line), mock- (dark grey line) and medium-incubated (light grey line) cultures. Neutralizing antibody titers are displayed in dashed grey lines according to the secondary y-axis (for details see caption of Figure 1B). Data of PBS-treated (#1 to #3) and FLUAVsw infected (#4 to #9) animals is shown in the time course following infections.
Figure 4Kinetics of FLUAVsw-specific IFN-γ-/TNF-α-/IL-2-producing CD4 T cells. Intracellular cytokine staining of defrosted PBMCs was performed following overnight in vitro restimulation with FLUAVsw (infection strain, MOI = 0.1; 18 h). Mock-incubated cultures served as negative controls. (A) CD4+ T cells were gated and analyzed for production of IFN-γ, TNF-α and IL-2. Contour plots show combinations of cytokines for selected time points following FLUAVsw infection. Exemplary data of animal #9 is shown. (B) Boolean gating was applied in order to identify single-, double-, and triple-cytokine-producing CD4+ T cells. Single- (dark grey), double- (orange) and triple- (red) cytokine-producing cells are shown as percent of total CD4+ T cells for all six infected animals in the time course following FLUAVsw infection.
Figure 5IFN-γ/TNF-α/IL-2 expression levels and CD8α/CD27 expression of cytokine-producing CD4 T cells. (A + B) Fluorescence intensity of IFN-γ, TNF-α and IL-2 expression within single- (dark grey), double- (orange) and triple- (red) cytokine-producing CD4+ T cells. (A) Histograms show exemplary data of animal #9 at six weeks post primary infection. Numbers indicate median fluorescence intensity (MFI) for each subset and the respective cytokine. (B) MFI of IFN-γ, TNF-α and IL-2 expression within single- (dark grey), double- (orange) and triple- (red) cytokine-producing CD4+ T cells isolated at six weeks post primary infection. Data of all six infected animals is shown by individual symbols. The mean is indicated by the black bar. (C) CD8α and CD27 expression on total CD4+ T cells (contour plot in the upper left and light grey dots in dot plots) and CD4+ T cells producing a single cytokine (dark grey dots, bottom), two cytokines (orange dots, middle) or three cytokines (red dots, top). Representative raw data of animal #9, six weeks post primary infection, is shown.
Figure 6Proliferation, degranulation and cytokine production by FLUAVsw-specific CD8β T cells. Violet-labeled PBMCs isolated at 2, 6 and 9 weeks post primary infection were restimulated twice with FLUAVsw (infection strain, MOI = 0.1; day 0 and day 5 of culture) and analyzed by FCM on day 6 of culture. (A) CD8β+ T cells were gated (not shown) and analyzed for violet proliferation, surface CD107a expression and intracellular accumulation of IFN-γ and TNF-α. Contour plots show all possible marker combinations. Exemplary raw data of one non-infected control animal (#3) and one infected animal (#8) is shown for week 6 post primary infection. (B) Boolean gating was applied in order to identify multifunctional CD8β+ T cells, and resulting CD8β+ T-cell subsets were grouped by number of functions. Displayed is the frequency of CD8β+ T cells carrying out two or more functions within total CD8β+ T cells. Data of six FLUAVsw-infected animals (#4-9) and two non-infected control animals (#1, #3) is shown.
Swine leukocyte antigen (SLA) haplotypes of pigs used in this study
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| 1 | Lr-25.0 | 11XX | 03XX | 07XX | Lr-0.22 | 06XX | 02XX(0204) | 02XX |
| Lr-45.0 | 08XX + cs02 | 07XX | w08XX + 10XX | Lr-0.25 | 13XX | 09XX | 04XX | |
| 2 | Lr-08.0 | 04XX | 03XX | 07XX | Lr-0.15b | 04XX | 02XX | 02XX |
| Lr-59.0 | 11XX(1103) | 05XX | jh02 | Lr-0.25 | 13XX | 09XX | 04XX | |
| 3 | Lr-24.0 | blank | 04XX/hb06 | 02XX | Lr-0.09 | 02XX | 04XX | 03XX |
| Lr-59.0 | 11XX(1103) | 05XX | jh02 | Lr-0.15b | 04XX | 02XX | 02XX | |
| 4 | Lr-01.0 | 01XX | 01XX | 01XX | Lr-0.15b | 04XX | 02XX | 02XX |
| Lr-25.0 | 11XX | 03XX | 07XX | Lr-0.25 | 13XX | 09XX | 04XX | |
| 5 | Lr-18.0 | 04XX | 03XX | 01XX | Lr-0.09 | 02XX | 04XX | 03XX |
| Lr-24.0 | blank | 04XX/hb06 | 02XX | Lr-0.15b | 04XX | 02XX | 02XX | |
| 6 | Lr-01.0 | 01XX | 01XX | 01XX | Lr-0.09 | 02XX | 04XX | 03XX |
| Lr-24.0 | blank | 04XX/hb06 | 02XX | Lr-0.15b | 04XX | 02XX | 02XX | |
| 7 | Lr-01.0 | 01XX | 01XX | 01XX | Lr-0.09 | 02XX | 04XX | 03XX |
| Lr-24.0 | blank | 04XX/hb06 | 02XX | Lr-0.15b | 04XX | 02XX | 02XX | |
| 8 | Lr-40.0 | 16XX | 05XX | 10XX | Lr-0.10 | 04XX | 08XX | 03XX |
| Lr-46.0 | 12XX | 04XX/hb06 | 06XX | Lr-0.23 | 10XX/er01 | 06XX/zs12 | 01XX | |
| 9 | Lr-01.0 | 01XX | 01XX | 01XX | Lr-0.33 | 11XX | 02XX | 02XX |
| Lr-01.0 | 01XX | 01XX | 01XX | Lr-0.35 | 01XX | 04XX | 02XX | |